Brokers Issue Forecasts for Landos Biopharma, Inc.’s Q1 2022 Earnings (NASDAQ:LABP)

Landos Biopharma, Inc. (NASDAQ:LABPGet Rating) – Investment analysts at Jefferies Financial Group issued their Q1 2022 earnings estimates for Landos Biopharma in a research note issued on Tuesday, April 12th. Jefferies Financial Group analyst C. Howerton forecasts that the company will post earnings per share of ($0.48) for the quarter. Jefferies Financial Group has a “Hold” rating on the stock. Jefferies Financial Group also issued estimates for Landos Biopharma’s Q3 2022 earnings at ($0.30) EPS, Q4 2022 earnings at ($0.27) EPS, FY2022 earnings at ($1.43) EPS, FY2023 earnings at ($1.21) EPS, FY2024 earnings at ($1.27) EPS, FY2025 earnings at ($1.01) EPS and FY2026 earnings at ($1.17) EPS.

Landos Biopharma (NASDAQ:LABPGet Rating) last released its earnings results on Thursday, March 24th. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.22).

LABP has been the subject of several other research reports. Raymond James reduced their price objective on shares of Landos Biopharma from $24.00 to $9.00 and set an “outperform” rating for the company in a research report on Friday, March 25th. Zacks Investment Research upgraded Landos Biopharma from a “hold” rating to a “buy” rating and set a $1.75 target price on the stock in a report on Wednesday, April 6th. Finally, JPMorgan Chase & Co. cut their target price on Landos Biopharma from $15.00 to $7.00 and set a “neutral” rating on the stock in a report on Monday, January 3rd. Four analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $21.75.

Shares of LABP stock opened at $1.27 on Thursday. Landos Biopharma has a 52 week low of $1.17 and a 52 week high of $16.17. The firm has a 50 day moving average of $1.78 and a 200-day moving average of $6.28.

A number of large investors have recently modified their holdings of the business. Acadian Asset Management LLC bought a new stake in shares of Landos Biopharma during the 4th quarter worth $39,000. Allworth Financial LP bought a new stake in shares of Landos Biopharma during the 3rd quarter worth $77,000. Morgan Stanley raised its stake in shares of Landos Biopharma by 1,337.0% during the 2nd quarter. Morgan Stanley now owns 6,912 shares of the company’s stock worth $81,000 after purchasing an additional 6,431 shares during the period. Goldman Sachs Group Inc. bought a new stake in shares of Landos Biopharma during the 4th quarter worth $84,000. Finally, Wells Fargo & Company MN raised its stake in shares of Landos Biopharma by 382.6% during the 2nd quarter. Wells Fargo & Company MN now owns 9,526 shares of the company’s stock worth $110,000 after purchasing an additional 7,552 shares during the period. Institutional investors and hedge funds own 65.67% of the company’s stock.

About Landos Biopharma (Get Rating)

Landos Biopharma, Inc, a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. The company's lead product candidate in development include omilancor, a gut-restricted oral therapeutic candidate that targets lanthionine synthetase C-like protein 2 (LANCL2) for the treatment of ulcerative colitis (UC), Crohn's disease (CD), and eosinophilic esophagitis; NX-13, a gut-restricted oral therapeutic that targets NOD-like receptor X1 (NOD-like), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines for UC and CD; and LABP-104, an orally-active and systemically bioavailable small molecule therapeutic candidate that targets LANCL2 agonist for the treatment of systemic lupus erythematosus and rheumatoid arthritis (RA).

Featured Stories

Earnings History and Estimates for Landos Biopharma (NASDAQ:LABP)

Receive News & Ratings for Landos Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Landos Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.